Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients

被引：30

作者：

Nakamura, Yasuhiro ^{[1
,27
]}

Namikawa, Kenjiro ^{[2
]}

Kiniwa, Yukiko ^{[3
]}

Kato, Hiroshi ^{[4
]}

Yamasaki, Osamu ^{[5
]}

Yoshikawa, Shusuke ^{[6
]}

Maekawa, Takeo ^{[7
]}

Matsushita, Shigeto ^{[8
]}

Takenouchi, Tatsuya ^{[9
]}

Inozume, Takashi ^{[10
]}

Nakai, Yasuo ^{[11
]}

Fukushima, Satoshi ^{[12
]}

Saito, Shintaro ^{[13
]}

Otsuka, Atsushi ^{[14
,15
]}

Fujimoto, Noriki ^{[16
]}

Isei, Taiki ^{[17
]}

Baba, Natsuki ^{[18
]}

Matsuya, Taisuke ^{[19
]}

Tanaka, Ryo ^{[20
]}

Kaneko, Takahide ^{[21
]}

Onishi, Masazumi ^{[22
]}

Kuwatsuka, Yutaka ^{[23
]}

Nagase, Kotaro ^{[24
]}

Onuma, Takehiro ^{[25
]}

Nomura, Motoo ^{[26
]}

Umeda, Yoshiyasu ^{[1
,20
]}

Yamazaki, Naoya ^{[2
]}

机构：

[1] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, Saitama, Japan

[2] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo, Japan

[3] Shinshu Univ, Dept Dermatol, Matsumoto, Japan

[4] Nagoya City Univ, Dept Geriatr & Environm Dermatol, Grad Sch Med Sci, Nagoya, Japan

[5] Okayama Univ, Dept Dermatol, Dent & Pharmaceut Sci, Grad Sch Med, Okayama, Japan

[6] Shizuoka Canc Ctr, Dermatol Div, Shizuoka, Japan

[7] Jichi Med Univ, Dept Dermatol, Tochigi, Japan

[8] Natl Hosp Org, Dept Dermato Oncol Dermatol, Kagoshima Med Ctr, Kagoshima, Japan

[9] Niigata Canc Ctr Hosp, Dept Dermatol, Niigata, Japan

[10] Chiba Univ, Dept Dermatol, Chiba, Japan

[11] Mie Univ, Dept Dermatol, Mie, Japan

[12] Kumamoto Univ, Fac Life Sci, Dept Dermatol & Plast Surg, Kumamoto, Japan

[13] Gunma Univ, Dept Dermatol, Grad Sch Med, Maebashi, Japan

[14] Kyoto Univ, Dept Dermatol, Kyoto, Japan

[15] Kindai Univ Hosp, Dept Dermatol, Osaka, Japan

[16] Shiga Univ Med Sci, Dept Dermatol, Otsu, Japan

[17] Osaka Int Canc Inst, Dept Dermatol Oncol, Osaka, Japan

[18] Univ Fukui, Dept Dermatol, Fukui, Japan

[19] Asahikawa Med Univ, Dept Dermatol, Asahikawa, Japan

[20] Kawasaki Med Sch, Dept Dermatol, Kurashiki, Japan

[21] Juntendo Univ, Dept Dermatol, Urayasu Hosp, Chiba, Japan

[22] Iwate Med Univ, Dept Dermatol, Iwate, Japan

[23] Nagasaki Univ, Dept Dermatol, Nagasaki, Japan

[24] Saga Univ, Fac Med, Dept Internal Med, Div Dermatol, Saga, Japan

[25] Univ Yamanashi, Dept Dermatol, Yamanashi, Japan

[26] Kyoto Univ, Dept Clin Oncol, Kyoto, Japan

[27] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, 1397-1 Yamane, Saitama 3501298, Japan

来源：

EUROPEAN JOURNAL OF CANCER | 2022年 / 176卷

关键词：

CTLA-4; antigen; Immunotherapy; Ipilimumab; Melanoma; Nivolumab; Pembrolizumab; Programmed cell death 1 receptor; Retrospective studies; Japan; SINGLE-ARM; OPEN-LABEL; PD-1; BLOCKADE; PHASE-II; MUCOSAL; IPILIMUMAB; INHIBITORS; NIVOLUMAB; MUTATION; SAFETY;

D O I：

10.1016/j.ejca.2022.08.030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Although anti-PD-1 antibody monotherapy (PD-1) is commonly used to treat advanced acral melanoma (AM), its efficacy is limited. Further, data on the efficacy of PD-1 plus anti-CTLA-4 antibody (PD-1+CTLA-4) for the treatment of AM are limited. Therefore, we compared the efficacy of PD-1+CTLA-4 and PD-1 in the treatment of Japanese patients with advanced AM. Methods: This retrospective study evaluated patients with advanced AM who were treated with PD-1 or PD-1+CTLA-4 as first-line immunotherapy in 24 Japanese institutions between 2014 and 2020. Treatment efficacy focussing on the objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) was compared between the two groups. Results: In total, 254 patients (palm and sole melanoma [PSM], n = 180; nail apparatus melanoma [NAM], n = 74) were included. Among the patients with PSM, the ORR (19% vs. 31%; P = 0.44), PFS (5.9 vs. 3.2 months; P = 0.74), and OS (23.1 vs. not reached; P = 0.55) did not differ significantly between the PD-1 and PD-1+CTLA-4 groups. Among the patients with NAM, the ORR (61% vs. 10%; P < 0.001) was significantly higher and PFS was longer (6.4 vs. 3.8 months; P = 0.10) in the PD-1+CTLA-4 group than in the PD-1 group. Cox multivariate analysis demonstrated that PD-1+CTLA-4 is an independent predictor of a favourable PFS in patients with NAM (P = 0.002). Conclusions: The efficacy of PD-1+CTLA-4 is not superior to that of PD-1 for the treatment of advanced PSM. However, PD-1+CTLA-4 may be more efficacious than PD-1 for the treatment of advanced NAM. (C) 2022 Elsevier Ltd. All rights reserved.

引用

页码：78 / 87

页数：10

共 41 条

[1] Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial [J].

Ascierto, Paolo A. ;

Long, Georgina V. ;

Robert, Caroline ;

Brady, Benjamin ;

Dutriaux, Caroline ;

Di Giacomo, Anna Maria ;

Mortier, Laurent ;

Hassel, Jessica C. ;

Rutkowski, Piotr ;

McNeil, Catriona ;

Kalinka-Warzocha, Ewa ;

Savage, Kerry J. ;

Hernberg, Micaela M. ;

Lebbe, Celeste ;

Charles, Julie ;

Mihalcioiu, Catalin ;

Chiarion-Sileni, Vanna ;

Mauch, Cornelia ;

Cognetti, Francesco ;

Ny, Lars ;

Arance, Ana ;

Svane, Inge Marie ;

Schadendorf, Dirk ;

Gogas, Helen ;

Saci, Abdel ;

Jiang, Joel ;

Rizzo, Jasmine ;

Atkinson, Victoria .

JAMA ONCOLOGY, 2019, 5 (02) :187-194

[2] BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma [J].

Bai, X. ;

Mao, L. L. ;

Chi, Z. H. ;

Sheng, X. N. ;

Gui, C. L. ;

Kong, Y. ;

Dai, J. ;

Wang, X. ;

Li, S. M. ;

Tang, B. X. ;

Lian, B. ;

Zhou, L. ;

Yan, X. Q. ;

Guo, J. ;

Si, L. .

NEOPLASMA, 2017, 64 (04) :626-632

[3] Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma [J].

Bhave, Prachi ;

Ahmed, Tasnia ;

Lo, Serigne N. ;

Shoushtari, Alexander ;

Zaremba, Anne ;

Versluis, Judith M. ;

Mangana, Joanna ;

Weichenthal, Michael ;

Si, Lu ;

Lesimple, Thierry ;

Robert, Caroline ;

Trojanello, Claudia ;

Wicky, Alexandre ;

Heywood, Richard ;

Tran, Lena ;

Batty, Kathleen ;

Dimitriou, Florentia ;

Stansfeld, Anna ;

Allayous, Clara ;

Schwarze, Julia K. ;

Mooradian, Meghan J. ;

Klein, Oliver ;

Mehmi, Inderjit ;

Roberts-Thomson, Rachel ;

Maurichi, Andrea ;

Yeoh, Hui-Ling ;

Khattak, Adnan ;

Zimmer, Lisa ;

Blank, Christian U. ;

Ramelyte, Egle ;

Kaehler, Katharina C. ;

Roy, Severine ;

Ascierto, Paolo A. ;

Michielin, Olivier ;

Lorigan, Paul C. ;

Johnson, Douglas B. ;

Plummer, Ruth ;

Lebbe, Celeste ;

Neyns, Bart ;

Sullivan, Ryan ;

Hamid, Omid ;

Santinami, Mario ;

McArthur, Grant A. ;

Haydon, Andrew M. ;

Long, Georgina, V ;

Menzies, Alexander M. ;

Carlino, Matteo S. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (07)

[4] MELANOMA WITHIN A SOUTHWESTERN HISPANIC POPULATION [J].

BLACK, WC ;

GOLDHAHN, RT ;

WIGGINS, C .

ARCHIVES OF DERMATOLOGY, 1987, 123 (10) :1331-1334

[5]

Bradford PT, 2009, ARCH DERMATOL, V145, P427, DOI 10.1001/archdermatol.2008.609

[6] Translational pathology, genomics and the development of systemic therapies for acral melanoma [J].

Chen, Yian Ann ;

Teer, Jamie K. ;

Eroglu, Zeynep ;

Wu, Jheng-Yu ;

Koomen, John M. ;

Karreth, Florian A. ;

Messina, Jane L. ;

Smalley, Keiran S. M. .

SEMINARS IN CANCER BIOLOGY, 2020, 61 :149-157

[7] Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases [J].

Chi, Zhihong ;

Li, Siming ;

Sheng, Xinan ;

Si, Lu ;

Cui, Chuanliang ;

Han, Mei ;

Guo, Jun .

BMC CANCER, 2011, 11

[8] Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma [J].

Fujisawa, Yasuhiro ;

Yoshikawa, Shusuke ;

Minagawa, Akane ;

Takenouchi, Tatsuya ;

Yokota, Kenji ;

Uchi, Hiroshi ;

Noma, Naoki ;

Nakamura, Yasuhiro ;

Asai, Jun ;

Kato, Jiinji ;

Fujiwara, Susumu ;

Fukushima, Satoshi ;

Uehara, Jiro ;

Hoashi, Toshihiko ;

Kaji, Tatsuya ;

Fujimura, Taku ;

Namikawa, Kenjiro ;

Yoshioka, Manabu ;

Murao, Naoki ;

Ogata, Dai ;

Matsuyama, Kanako ;

Hatta, Naohito ;

Shibayama, Yoshitsugu ;

Fujiyama, Toshiharu ;

Ishikawa, Masashi ;

Yamada, Daisuke ;

Kishi, Akiko ;

Nakamura, Yoshiyuki ;

Shimiauchi, Takatoshi ;

Fujii, Kazuyasu ;

Fujimoto, Manabu ;

Ihn, Hironobu ;

Katoh, Norito .

CANCER MEDICINE, 2019, 8 (05) :2146-2156

[9] Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual [J].

Gershenwald, Jeffrey E. ;

Scolyer, Richard A. ;

Hess, Kenneth R. ;

Sondak, Vernon K. ;

Long, Georgina V. ;

Ross, Merrick I. ;

Lazar, Alexander J. ;

Faries, Mark B. ;

Kirkwood, John M. ;

McArthur, Grant A. ;

Haydu, Lauren E. ;

Eggermont, Alexander M. M. ;

Flaherty, Keith T. ;

Balch, Charles M. ;

Thompson, John F. .

CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (06) :472-492

[10] Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification [J].

Guo, Jun ;

Si, Lu ;

Kong, Yan ;

Flaherty, Keith T. ;

Xu, Xiaowei ;

Zhu, Yanyan ;

Corless, Christopher L. ;

Li, Li ;

Li, Haifu ;

Sheng, Xinan ;

Cui, Chuanliang ;

Chi, Zhihong ;

Li, Siming ;

Han, Mei ;

Mao, Lili ;

Lin, Xuede ;

Du, Nan ;

Zhang, Xiaoshi ;

Li, Junling ;

Wang, Baocheng ;

Qin, Shukui .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (21) :2904-2909

← 1 2 3 4 5 →